Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2022-09-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
恩威医药股份有限公司首次公开发行股票并在创业板上市网上定价发行摇号中签结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the lottery results for the online pricing issuance of shares in the initial public offering (IPO) of Enwei Pharmaceutical Co., Ltd. It details the number of shares issued, the pricing, the lottery process, and instructions for investors who won the lottery to pay for their shares. There is no financial report, management discussion, or detailed financial data presented. The document is a formal announcement of the lottery results related to the IPO share issuance, which fits the category of Capital/Financing Update (CAP) as it relates to fundraising and issuance of new shares.
2022-09-07 Chinese
恩威医药股份有限公司首次公开发行股票并在创业板上市网上定价发行申购情况及中签率公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 恩威医药股份有限公司, detailing the subscription situation, number of shares issued, subscription rates, and the lottery results for share allocation. It includes information about the underwriting, subscription process, and payment obligations for investors. There is no financial report, earnings data, or management discussion. The document is a formal announcement about the share issuance and subscription results, which fits the category of Share Issue/Capital Change (SHA). The document length is short (2043 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is SHA with high confidence.
2022-09-06 Chinese
恩威医药股份有限公司首次公开发行股票并在创业板上市投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票并在创业板上市投资风险特别公告" which translates to "Special Announcement on Investment Risks for Initial Public Offering and Listing on the ChiNext Market." It discusses the IPO process, pricing, subscription details, risks related to the issuance, and regulatory approvals. It is not a full financial report but rather an announcement related to the capital raising event and associated risks. The document length is about 6,892 characters, which is substantial but the content is focused on the IPO issuance and risk disclosure rather than detailed financial statements or earnings. Therefore, this fits best under the category of Capital/Financing Update (CAP), as it provides detailed information about the company's fundraising activity and issuance terms.
2022-09-04 Chinese
恩威医药股份有限公司首次公开发行股票并在创业板上市发行公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Enwei Pharmaceutical Co., Ltd., including the issuance price, number of shares, underwriting details, industry comparisons, and investment risk disclosures. It references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and provides extensive financial and business information to potential investors. The document is not a full annual or quarterly report, nor is it a transcript, audit report, or management change announcement. It is a formal public announcement of a capital raising event through stock issuance and listing on the Growth Enterprise Market (创业板). Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report publication (RPA) or a regulatory filing (RNS).
2022-09-04 Chinese
法律意见书
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the initial public offering (IPO) and listing of a company on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It references various Chinese laws and regulations related to securities issuance, company law, and stock exchange listing rules. The document discusses the company's qualifications, approvals, shareholder structure, business operations, and compliance with regulatory requirements for the IPO. It also mentions audit reports and internal control reports but does not itself contain financial statements or earnings data. The document is a legal opinion and work report supporting the IPO process, not an earnings release, annual report, or other financial report. It is not a brief announcement but a comprehensive legal opinion document. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory compliance document related to the IPO process that does not fit into other specific categories like Annual Report or Capital/Financing Update.
2022-09-01 Chinese
恩威医药股份有限公司首次公开发行股票并在创业板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive information about the stock issuance, risk factors, financial data, management commitments, and legal agreements related to the IPO. The document is titled '招股说明书' which translates to 'Prospectus' or 'Offering Circular'. This type of document is specifically related to capital raising and stock issuance activities. It is not an annual report, earnings release, or any other type of report. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), which covers updates on company fundraising and financing activities such as IPO prospectuses.
2022-09-01 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.